Background. The relevance of the search for new drugs for the treatment of chronic heart failure (CHF) is attributable to the high morbidity, high mortality of patients with CHF, as well as the increasing number of multimorbid patients. In the pathogenesis of CHF, an important role is played by the vasoconstrictor and vasodilator effects of tissue neurohormones of the renin-angiotensin-aldosterone system (RAAS), which determine the progression of decompensation of the cardiovascular system in response to antigotensin-II-mediated myocardial remodeling and a decrease in cardiac output.
Objective. Identification of the most significant polymorphic variants of the RAAS genes that determine the effectiveness of therapy for cardiovascular diseases with type 1 angiotensin II receptor blockers (ARBs) based on an analysis of the scientific literature
Methods. During the period from January to September 2023, a search was conducted in the PubMed and Google Scholar databases using the following keywords: heart failure, angiotensin II receptor antagonists, antihypertensive drugs, RAAS gene polymorphisms, angiotensin II, angiotensinogen, aldosterone synthase, angiotensin-converting enzym, single nucleotide poly-
morphism (SNP).
Results. ARB receptor blockers, widely used in the treatment of CHF at present, have a positive effect on hemodynamic parameters and ensure the reverse development of left ventricular hypertrophy. Several genetic polymorphisms that may be involved in the pathogenesis of cardiovascular diseases and also alter the pharmacological response to ARB therapy have been described.
Conclusion. Identification of allelic variants of genes encoding components of the RAAS may contribute to a differentiated approach to the selection of individual ARBs, but at present there is not yet a sufficient evidence base to develop any standard panel of polymorphisms to be evaluated for the development of clinical recommendations for personalized selection of drugs of the group under discussion.

Keywords: aldosterone synthase angiotensin-converting enzyme, RAAS gene polymorphisms, angiotensin II receptor antagonists, angiotensin II, antihypertensive drugs, angiotensinogen, heart failure